Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576)
Taiwan
· Delayed Price · Currency is TWD 79.10
-0.50 (-0.63%)
Sep 10, 2024, 1:30 PM CST
Foresee Pharmaceuticals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -859 | -1,036 | -472.64 | -569.27 | -510.71 | -487.21 | Upgrade
|
| Depreciation & Amortization | 78.91 | 73.45 | 50.93 | 51.16 | 48.71 | 37.36 | Upgrade
|
| Other Amortization | 0.17 | 0.18 | 0.22 | 0.32 | 0.77 | 1.84 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.03 | 0.2 | 0.31 | 0.13 | 0.06 | 2.86 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 1.16 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | -0.29 | -0.8 | -0.52 | -0.22 | Upgrade
|
| Stock-Based Compensation | 43.67 | 50.77 | 40.18 | 23.92 | 22.89 | 19.43 | Upgrade
|
| Other Operating Activities | -11.56 | 0.5 | 0.69 | -9.42 | 4.56 | 0.49 | Upgrade
|
| Change in Accounts Receivable | 1 | -49.64 | -16.27 | - | 0.01 | 0.1 | Upgrade
|
| Change in Inventory | 20.64 | 49.61 | -151.53 | 40.1 | 32.82 | - | Upgrade
|
| Change in Accounts Payable | 5.69 | -10.72 | 22.85 | - | 7.12 | -78.37 | Upgrade
|
| Change in Unearned Revenue | -0.51 | -1.01 | -1.8 | 160.76 | 23.77 | 55.43 | Upgrade
|
| Change in Other Net Operating Assets | -50.9 | 35.41 | -4.79 | 34.76 | -1.27 | 48.42 | Upgrade
|
| Operating Cash Flow | -771.87 | -887.56 | -233.22 | -213.33 | -674.8 | -447.82 | Upgrade
|
| Capital Expenditures | -52.39 | -46.28 | -58.07 | -6.86 | -12.79 | -86.53 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.21 | 0.23 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | -0.54 | -15.4 | -85.34 | Upgrade
|
| Investment in Securities | 44.2 | -249 | 100 | 25 | -125 | - | Upgrade
|
| Other Investing Activities | -0.78 | -1.03 | -1.23 | 0.02 | 0.15 | -0.54 | Upgrade
|
| Investing Cash Flow | -8.77 | -296.08 | 40.7 | 17.62 | -153.03 | -172.4 | Upgrade
|
| Short-Term Debt Issued | - | 300 | - | - | 40 | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 84.53 | - | Upgrade
|
| Total Debt Issued | 400 | 300 | - | - | 124.53 | - | Upgrade
|
| Short-Term Debt Repaid | - | -100 | - | -30.07 | -9.93 | - | Upgrade
|
| Long-Term Debt Repaid | - | -15.52 | -11.35 | -84.1 | -10.63 | -11.16 | Upgrade
|
| Total Debt Repaid | -316.22 | -115.52 | -11.35 | -114.17 | -20.56 | -11.16 | Upgrade
|
| Net Debt Issued (Repaid) | 83.78 | 184.48 | -11.35 | -114.17 | 103.97 | -11.16 | Upgrade
|
| Issuance of Common Stock | 12.98 | 1,319 | 14.21 | 38.43 | 1,425 | 866.53 | Upgrade
|
| Financing Cash Flow | 96.76 | 1,504 | 2.86 | -75.74 | 1,529 | 855.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | 8.38 | -0.09 | 7.73 | -2.23 | -3.71 | -1.46 | Upgrade
|
| Net Cash Flow | -675.5 | 320.17 | -181.93 | -273.68 | 697.1 | 233.68 | Upgrade
|
| Free Cash Flow | -824.27 | -933.84 | -291.29 | -220.19 | -687.58 | -534.34 | Upgrade
|
| Free Cash Flow Margin | -251.93% | -478.80% | -96.61% | -97.42% | -298.38% | -710.58% | Upgrade
|
| Free Cash Flow Per Share | -6.06 | -7.34 | -2.47 | -1.88 | -6.78 | -5.57 | Upgrade
|
| Cash Interest Paid | 5.33 | 2.68 | 0.4 | 0.76 | 0.92 | 0.52 | Upgrade
|
| Cash Income Tax Paid | 63.43 | 46.01 | 29.01 | 41.66 | 26.65 | 17.63 | Upgrade
|
| Levered Free Cash Flow | -455.5 | -616.79 | -402.03 | -236.28 | -259.81 | -430.67 | Upgrade
|
| Unlevered Free Cash Flow | -452.42 | -615.01 | -401.78 | -235.85 | -259.19 | -430.35 | Upgrade
|
| Change in Net Working Capital | -14.22 | 63.36 | 141.64 | -32.78 | 0.39 | 23.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.